My ePortfolio Register   

A biological perspective for personalising immunotherapies

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.12.17
Views: 113

Dr Tom Lillie - Head of European Clinical Development, MSD, London, UK

Tom Lillie talks to ecancer at EAPM 2017 in Belfast.

He spoke mainly about the development of pembrolizumab and the different responses in various tumour types. 

He also is pursuing an avenue of treatment by looking at tumours with high mutational loads.

Rather than ending up with a single drug for single case scenario, Dr Lille sees it as a particular combination of drugs to treat more specific cases.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence